QT interval prolongation among patients treated with angiogenesis inhibitors

Targeted Oncology

Volumn 4, Issue 2, 2009, Pages 89-97

  Ederhy, Stephane ^a,d   Cohen, Ariel ^a,d   Dufaitre, Ghislaine ^a,d   Izzedine, Hassan ^b,d   Massard, Christophe ^c,e   Meuleman, Catherine ^a,d   Besse, Benjamin ^c,e   Berthelot, Emmanuelle ^a,d   Boccara, Franck ^a,d   Soria, Jean Charles ^c,e  

^a Saint Antoine University   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d SORBONNE UNIVERSITÉ   (France)

^e UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

Angiogenic inhibitors QT prolongation; Cardiovascular toxicities; Molecular targeted therapy

Indexed keywords

ANGIOGENESIS INHIBITOR; BCR ABL PROTEIN; BMS 334825; CISPLATIN; COLONY STIMULATING FACTOR 1; DOCETAXEL; ENZASTAURIN; GEMCITABINE; HISTONE DEACETYLASE INHIBITOR; NILOTINIB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE C INHIBITOR; PROTEIN RET; PROTEIN TYROSINE KINASE; ROMIDEPSIN; STEM CELL FACTOR RECEPTOR; SUNITINIB; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIANGIOGENIC ACTIVITY; BLOOD TOXICITY; BREAST CANCER; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CHRONIC MYELOID LEUKEMIA; DIARRHEA; DRUG MONITORING; DRUG TARGETING; ELECTROCARDIOGRAPHY; ELECTROLYTE BLOOD LEVEL; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; HAND FOOT SYNDROME; HEART REPOLARIZATION; HUMAN; HYPOTHYROIDISM; INCIDENCE; KIDNEY CANCER; LONG QT SYNDROME; LUNG NON SMALL CELL CANCER; METASTASIS; MOLECULAR TARGETED THERAPY; MUCOSA INFLAMMATION; NAUSEA; NONHUMAN; NORMAL VALUE; PATIENT INFORMATION; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; RAT; REVIEW; RISK FACTOR; TORSADE DES POINTES; VOMITING;

ANGIOGENESIS INHIBITORS; ARRHYTHMIAS, CARDIAC; DRUG EVALUATION, PRECLINICAL; ELECTRIC COUNTERSHOCK; ELECTROCARDIOGRAPHY; HEART; HUMANS; HYPERTENSION; MAGNESIUM; PROTEIN KINASE INHIBITORS; VENOUS THROMBOSIS; VENTRICULAR DYSFUNCTION; WITHHOLDING TREATMENT;

EID: 67349251502     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-009-0111-3     Document Type: Review

References (51)

1. JM Roodhart MH Langenberg E Witteveen EE Voest 2008 The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway Curr Clin Pharmacol 3 132 143
2. LM Ellis DJ Hicklin 2008 VEGF-targeted therapy: mechanisms of anti-tumour activity Nat Rev Cancer 8 579 591
3. O Rixe B Billemont H Izzedine 2007 Hypertension as a predictive factor of Sunitinib activity Ann Oncol 18 6 1117 (Pubitemid 47050505)
4. T Force DS Krause RA Van Etten 2007 Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition Nat Rev Cancer 7 332 344 (Pubitemid 46652481)
5. M Schmidinger CC Zielinski UM Vogl 2008 Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma J Clin Oncol 26 5204 5212
6. TE Hutson RA Figlin JG Kuhn RJ Motzer 2008 Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies Oncologist 13 1084 1096
7. EL Strevel DJ Ing LL Siu 2007 Molecularly targeted oncology therapeutics and prolongation of the QT interval J Clin Oncol 25 3362 3371 (Pubitemid 47325624)
8. DM Hutton 2008 The importance of routine QT interval measurement in rhythm interpretation Dynamics 19 29 33
9. AM Issa KA Phillips S Van Bebber 2007 Drug withdrawals in the United States: a systematic review of the evidence and analysis of trends Curr Drug Saf 2 177 185 (Pubitemid 47578123)
10. HM Vargas AS Bass A Breidenbach 2008 Scientific review and recommendations on preclinical cardiovascular safety Safety pharmacology in focus: new methods developed in the light of the ICH S7B guidance document J Pharmacol Toxicol Methods 58 72 76
11. H Morita J Wu DP Zipes 2008 The QT syndromes: long and short Lancet 372 750 763
12. R Schimpf M Borggrefe C Wolpert 2008 Clinical and molecular genetics of the short QT syndrome Curr Opin Cardiol 23 192 198
13. K Ahmad P Dorian Suppl 4 2007 Drug-induced QT prolongation and proarrhythmia: an inevitable link? Europace 9 iv16 22
14. C Antzelevitch Suppl 4 2007 Ionic, molecular, and cellular bases of QT-interval prolongation and torsade de pointes Europace 9 iv4 15
15. A Gupta AT Lawrence K Krishnan 2007 Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes Am Heart J 153 891
16. SM Al-Khatib NM LaPointe JM Kramer 2003 What clinicians should know about the QT interval JAMA 289 2120 2127 (Pubitemid 37430214)
17. S Viskin U Rosovski AJ Sands E Chen 2005 Inaccurate electrocardiographic interpretation of long QT: the majority of physicians cannot recognize a long QT when they see one Heart Rhythm 2 569 574 (Pubitemid 40724120)
18. JC Soria V Dieras V Girre 2007 QTc monitoring during a phase I study: experience with SR271425 Am J Clin Oncol 30 106 112 (Pubitemid 46573247)
19. Rubel P, Hamidi S, Behlouli H et al (1996) Are serial Holter QT, late potential, and wavelet measurement clinically useful? J Electrocardiol 29 Suppl:52-61 (Pubitemid 27051634)
20. B Charbit E Samain P Merckx 2006 QT interval measurement: evaluation of automatic QTc measurement and new simple method to calculate and interpret corrected QT interval Anesthesiology 104 255 260
21. MJ Yarnoz AB Curtis 2008 More reasons why men and women are not the same (gender differences in electrophysiology and arrhythmias) Am J Cardiol 101 1291 1296
22. P Davey 2002 How to correct the QT interval for the effects of heart rate in clinical studies J Pharmacol Toxicol Methods 48 3 9 (Pubitemid 36577173)
23. I Goldenberg AJ Moss 2008 Long QT syndrome J Am Coll Cardiol 51 2291 2300
24. D Zeltser D Justo A Halkin 2003 Torsade de pointes due to noncardiac drugs: most patients have easily identifiable risk factors Medicine 82 282 290 (Pubitemid 36859224)
25. MT Meinardi DJ van Veldhuisen JA Gietema 2001 Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients J Clin Oncol 19 2746 2753 (Pubitemid 32441381)
26. M Varterasian M Meyer H Fingert 2003 Baseline heart rate-corrected QT and eligibility for clinical trials in oncology J Clin Oncol 21 3378 3379
27. A Trotti AD Colevas A Setser 2003 CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment Semin Radiat Oncol 13 176 181 (Pubitemid 36962641)
28. BS Mann JR Johnson 2007 FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma The Oncologist 12 10 1247 1252 (Pubitemid 350106355)
29. Gu W, Roeder RG (1997) Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain 90:595-606
30. RL Piekarz R Robey V Sandor S Bakke 2001 Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report Blood 98 2865 2868
31. MH Shah P Binkley K Chan J Xiao 2006 Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors Clin Cancer Res 12 3997 4003 (Pubitemid 44078086)
32. RL Piekarz AR Frye JJ Wright SM Steinberg 2006 Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma Clin Cancer Res 12 3762 3773 (Pubitemid 44000258)
33. Y Oh RS Herbst H Burris A Cleverly 2008 Enzastaurin, an oral serine/threonine kinase inhibitor, as second- or third-line therapy of non-small-cell lung cancer J Clin Oncol 26 1135 1141
34. MA Carducci L Musib MS Kies 2006 Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer J Clin Oncol 24 4092 4099 (Pubitemid 46622284)
35. JM Rademaker-Lakhai LV Beerepoot N Mehra 2007 Phase I pharmacokinetic and pharmacodynamic study of the oral protein kinase C beta-inhibitor enzastaurin in combination with gemcitabine and cisplatin in patients with advanced cancer Clin Cancer Res 13 4474 4781
36. RJ Motzer BI Rini RM Bukowski BD Curti 2006 Sunitinib in patients with metastatic renal cell carcinoma JAMA 295 2516 2524 (Pubitemid 43854967)
37. VL Goodman EP Rock R Dagher RP Ramchandani 2007 Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma Clin Cancer Res 13 5 1367 1373 (Pubitemid 46450424)
38. D Mannavola P Coco G Vannucchi R Bertuelli 2007 A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake J Clin Endocrinol Metab 92 9 3531 3534 (Pubitemid 47435331)
39. TF Chu MA Rupnick R Kerkela 2007 Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib Lancet 370 9604 2011 2019 (Pubitemid 350236338)
40. US Food and Drug Administration (FDA) (2006) Dasatinib (BMS-35825) Oncologic Drug Advisory Committee Briefing Document NDA 21-96. Washington, DC, FDA, pp 52
41. RS Herbst JV Heymach MS O'Reilly 2007 Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis Expert Opin Investig Drugs 16 239 249 (Pubitemid 46206638)
42. KD Miller J Manuel Trigo C Wheeler 2005 Multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastastic breast cancer Clin Cancer Res 11 3369 3376 (Pubitemid 40627889)
43. T Tamura H Minami Y Yamada 2006 A phase I dose-escalation study of ZD6474 in Japanese patients with solid malignant tumors J Thorac Oncol 1 9 1002 1009 (Pubitemid 47181370)
44. SN Holden SG Eckhardt R Basser 2005 Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors Ann Oncol 16 1391 1397 (Pubitemid 41158486)
45. JV Heymach BE Johnson D Prager 2007 Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer J Clin Oncol 25 27 4270 4277 (Pubitemid 47548567)
46. MJ Kovacs DE Reece D Marcellus 2006 A phase II study of ZD6474 (Zactima, a selective inhibitor of VEGFR and EGFR tyrosine kinase in patients with relapsed multiple myeloma-NCIC CTG IND.145 Invest New Drugs 24 6 529 535 (Pubitemid 44273029)
47. KD Miller JM Trigo C Wheeler 2005 A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer Clin Cancer Res 11 9 3369 3376 (Pubitemid 40627889)
48. K Kiura K Nakagawa T Shinkai 2008 A randomized, double-blind, phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer J Thorac Oncol 3 4 386 393
49. M Hazarika X Jiang Q Liu 2008 Tasigna for chronic and accelerated phase Philadelphia chromosome-positive chronic myelogenous leukemia resistant to or intolerant of imatinib Clin Cancer Res 14 17 5325 5331
50. CS Tam H Kantarjian G Garcia-Manero 2008 Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia Blood 112 3 516 518
51. D Zeltser D Justo A Halkin 2003 Torsade de pointes due to noncardiac drugs: most patients have easily identifiable risk factors Medicine (Baltimore) 82 282 290 (Pubitemid 36859224)